Current Progress and Future Directions for Tau-Based Fluid Biomarker Diagnostics in Alzheimer’s Disease

Despite continued efforts, there remain no disease-modifying drugs approved by the United States Food and Drug Administration (FDA) or European Medicines Agency (EMA) to combat the global epidemic of Alzheimer’s disease. Currently approved medicines are unable to delay disease progression and are li...

Descripción completa

Detalles Bibliográficos
Autores principales: Arastoo, Mohammad, Lofthouse, Richard, Penny, Lewis K., Harrington, Charles R., Porter, Andy, Wischik, Claude M., Palliyil, Soumya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7698492/
https://www.ncbi.nlm.nih.gov/pubmed/33212983
http://dx.doi.org/10.3390/ijms21228673

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7698492/
https://www.ncbi.nlm.nih.gov/pubmed/33212983
http://dx.doi.org/10.3390/ijms21228673

Ejemplares similares